Dongcheng Biochem: 225Ac-LNC1011 injection has received clinical trial approval
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, Dongcheng Biochem announced that its holding subsidiary Yantai LNC Biotechnology Co., Ltd. (referred to as "LNC") has received the clinical trial approval notice for the drug 225Ac-LNC1011 issued by the National Medical Products Administration of China, and will soon conduct clinical trials for prostate cancer
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments